Organo Corp. (6368) AI Stock Analysis

• Market Cap: ¥604.82B
• Dividend Yield: 1.31%
• Average Volume (3M): 262.12K
• Price to Earnings (P/E): 22.0
• Beta (1Y): 1.50
• Revenue Growth: 7.87%
• EPS Growth: 38.32%
• Country: JP
• Employees: 2,512
• Sector: Industrials
• Sector Strength: 72
• Industry: Industrial - Pollution & Treatment Controls
• EPS (TTM): 171.53
• Shares Outstanding: 46,359,700
• 10 Day Avg. Volume: 368,090
• 30 Day Avg. Volume: 262,123
• PEG Ratio: 0.31
• Price to Book (P/B): 2.42
• Price to Sales (P/S): 1.79
• P/FCF Ratio: 11.04
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 594.77
• Revenue Forecast (FY): ¥176.72B

• Rating: 76 Outperform
• Price Target: ¥14,409.00 ▲(22.21% Upside)

Organo Corp. exhibits strong financial performance and positive technical indicators, driving the stock's favorable outlook. The valuation is moderate, with a reasonable P/E ratio and low dividend yield. The absence of earnings call and corporate events data does not impact the overall score.

Organo Corp. Business Overview & Revenue Model

Company Description

Organo Corp. (6368) is a leading company in the field of biotechnology and healthcare, specializing in the development and distribution of innovative solutions for health and wellness. The company operates primarily in the biopharmaceutical sector, focusing on research and development of therapeutic products and supplements that cater to various health conditions. With a commitment to enhancing the quality of life through science-driven products, Organo Corp. also engages in partnerships with healthcare providers and research institutions to expand its product offerings and improve patient outcomes.

How the Company Makes Money

Organo Corp. generates revenue through multiple streams, primarily from the sale of its biopharmaceutical products and health supplements. The company leverages a direct-to-consumer model, allowing it to capture retail margins and build brand loyalty. Additionally, revenue is supplemented through collaborations with healthcare providers, where Organo Corp. receives fees for product placements and joint marketing initiatives. Strategic partnerships with research institutions also contribute to revenue through grants and funding for joint research projects aimed at developing new therapies. Furthermore, the company may monetize its intellectual property through licensing agreements for its proprietary technologies and formulations.

Organo Corp. Financial Statement Overview

Summary

Organo Corp. demonstrates strong financial performance with notable revenue growth and improved profitability. The balance sheet is stable with prudent leverage, and cash flow shows resilience and effective cash generation.

Income Statement

Organo Corp. has shown strong revenue growth, with a consistent increase in total revenue over the years, indicating a positive trajectory. The gross profit margin has improved, reflecting efficient cost management. Notably, the net profit margin has strengthened markedly, showcasing enhanced profitability. EBIT and EBITDA margins have also shown consistent improvement, underscoring robust operational performance.

Balance Sheet

The balance sheet of Organo Corp. reveals a solid equity position, with a favorable equity ratio indicating financial stability. The debt-to-equity ratio is within a reasonable range, suggesting manageable leverage levels. Additionally, the company has shown a strong return on equity, reflecting effective utilization of shareholder funds and solid profitability.

Cash Flow

Organo Corp.'s cash flow statement indicates a strong recovery in operating cash flow, supporting a positive free cash flow trend. The operating cash flow to net income ratio is robust, confirming effective cash conversion. Meanwhile, the free cash flow to net income ratio has improved, signaling efficient capital management despite past fluctuations.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	169.76B	163.27B	150.36B	132.43B	112.07B	100.64B
Gross Profit	58.45B	55.18B	43.84B	34.98B	28.51B	26.33B
EBITDA	36.63B	34.53B	25.88B	18.02B	14.15B	11.02B
Net Income	25.12B	24.15B	17.31B	11.73B	9.21B	7.07B
Balance Sheet
Total Assets	190.39B	194.40B	182.70B	164.85B	130.51B	115.01B
Cash, Cash Equivalents and Short-Term Investments	20.57B	16.75B	17.64B	15.56B	20.20B	12.80B
Total Debt	28.15B	22.56B	36.47B	33.02B	15.63B	16.00B
Total Liabilities	71.01B	73.20B	80.56B	78.48B	54.50B	47.65B
Stockholders Equity	119.38B	120.95B	101.93B	86.17B	75.84B	67.21B
Cash Flow
Free Cash Flow	0.00	26.54B	2.08B	-19.99B	7.99B	-5.84B
Operating Cash Flow	0.00	28.80B	3.73B	-18.54B	10.79B	-4.58B
Investing Cash Flow	0.00	-2.13B	-1.42B	-1.31B	-1.52B	-1.26B
Financing Cash Flow	0.00	-20.82B	-641.00M	14.71B	-2.59B	4.93B

Organo Corp. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11790.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6368, the sentiment is Positive. The current price of 11790 is below the 20-day moving average (MA) of 12632.25, below the 50-day MA of 11965.85, and above the 200-day MA of 8938.07, indicating a bullish trend. The MACD of 479.33 indicates Negative momentum. The RSI at 68.37 is Neutral, neither overbought nor oversold. The STOCH value of 59.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6368.

Organo Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
6331	79 Outperform	€81.56B	13.02	16.37%	2.83%	31.48%	16.10%
9551	76 Outperform	$121.17B	14.74	12.54%	1.65%	13.86%	51.05%
6368	76 Outperform	¥604.82B	22.00	―	1.31%	7.87%	38.32%
6332	72 Outperform	¥107.27B	12.23	―	3.75%	2.46%	533.70%
6013	71 Outperform	¥190.58B	20.12	8.81%	3.16%	-1.58%	-3.07%
6370	67 Neutral	$653.37B	32.19	6.61%	1.61%	5.02%	-27.41%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%